From a technical perspective, Guardant Health (GH) is looking like an interesting pick, as it just reached a key level of support. GH recently overtook the 200-day moving average, and this suggests a long-term bullish trend. The 200-day simple moving average helps traders and analysts determine overall long-term market trends for stocks, commodities, indexes, and other financial instruments. The indicator moves higher or lower along with longer-term price moves, serving as a support or resistance level. GH ...

Guardant Health (GH) stock rocketed Friday after a Food and Drug Administration panel recommended the agency approve Guardant's blood-based colon cancer screening test. X The FDA's Medical Devices Advisory Committee voted eight to one that Guardant's blood-based test, known as Shield, is safe. Six out of nine panelists said the test appears effective, and seven to two voted that the benefits outweigh the risks. If approved, Guardant's blood-based test would rival Exact Sciences' (EXAS) Cologuard, an already ...

财务数据和关键指标变化 - 总收入增长31%至1.685亿美元,主要由精准肿瘤检测业务收入增长38%至1.562亿美元带动 [9][36] - 临床检测量增长20%至46,900个,主要由Guardant360检测量增长带动 [10][37] - 生物制药检测量增长37%至8,450个,支持生物制药业务收入增长40%至3,050万美元 [10][38] 各条业务线数据和关键指标变化 - 精准肿瘤检测业务临床检测收入增长37%至1.257亿美元,主要由Guardant360检测量增长带动 [37] - 精准肿瘤检测业务生物制药检测收入增长40%至3,050万美元,主要由检测量增长带动 [38] - 开发服务及其他收入为1,230万美元,与预期一致 [38] 各个市场数据和关键指标变化 - 美国Guardant360检测量增长,日本和英国也有贡献 [37] - Reveal和TissueNext检测量也持续增长 [37] 公司战略和发展方向及行业竞争 - 公司推出了新的智能液体活检平台,可以提供更多生物学洞见,如检测肿瘤组织来源和亚型,以及预测心脏不良事件等 [19][20] - 公司正在推进Reveal在结直肠癌和乳腺癌的医保报销进程,并计划开展肺癌、胰腺癌和胃癌的临床研究 [21][22] - Shield血液筛查测试在临床试验和FDA审批过程中取得进展,有望成为首个获批的Medicare报销的结直肠癌筛查血液检测 [27][29] 管理层对经营环境和未来前景的评论 - 公司在精准肿瘤检测业务方面实现了正现金流,并预计Reveal业务将在2025年实现毛利润正值 [22][23] - 公司有信心未来可以实现超过60%的MRD业务毛利率 [23] - 公司预计2024年总收入将增长20%-21%至6.75-6.85亿美元,非GAAP毛利率(不含筛查业务)将为61%-63% [47][48] - 公司预计2024年自由现金流为-2.75至-2.85亿美元,较之前预期有所改善 [43][49] 问答环节重要的提问和回答 问题1 **Mark Massaro 提问** 关注FDA咨询委员会会议将讨论Shield的安全性、有效性以及获益/风险比等问题,是否会有关于标签的讨论成为重点 [53] **AmirAli Talasaz 回答** FDA将在会议前几天公布最终议程,公司对数据质量和设备性能充满信心,将积极参与讨论 [54] 问题2 **Jack Meehan 提问** 询问Guardant360的ASP和检测量增长情况 [58] **Michael Bell 和 Helmy Eltoukhy 回答** 第一季度Guardant360 ASP上升至2,900-2,950美元,主要由于Medicare和商业支付的改善;检测量增长也较好,未来有望进一步提升 [59][60][61] 问题3 **Daniel Arias 提问** 询问Reveal业务的收入目标和公司是否会放开限制Reveal检测量 [63] **Helmy Eltoukhy 回答** 公司目前正在管控Reveal检测量以控制现金流,但随着成本下降和ASP改善,预计2025年Reveal将实现毛利润正值,屆时将大幅增加检测量 [65][66]

For the quarter ended March 2024, Guardant Health (GH) reported revenue of $168.49 million, up 30.9% over the same period last year. EPS came in at -$0.46, compared to -$1.30 in the year-ago quarter. The reported revenue represents a surprise of +11.94% over the Zacks Consensus Estimate of $150.51 million. With the consensus EPS estimate being -$0.72, the EPS surprise was +36.11%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...

Guardant Health (GH) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.30 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 36.11%. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.93 per share when it actually produced a loss of $1.58, delivering a surprise of -69.89%. Over the last four qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specif ...

Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif. May 9, 2024 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights • Revenue of $168.5 million for the first quarter of 2024, an increase of 31% over the first quarte ...

Guardant Health (GH) is scheduled to report first-quarter 2024 results on May 9, after market close. In the last reported quarter, the company’s earnings missed expectations by 69.89%. Factors to Consider The Zacks Consensus Estimate for Guardant’s total revenues is pegged at around $151 million, while the same for earnings is pegged at a loss of 72 cents per share. Both metrics indicate improvements over the year-ago quarter’s levels. Through its screening business, Guardant intends to provide critical ins ...

Wall Street analysts expect Guardant Health (GH) to post quarterly loss of $0.72 per share in its upcoming report, which indicates a year-over-year increase of 44.6%. Revenues are expected to be $150.51 million, up 16.9% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Before a company announces its earnings, it is essential ...

公司背景 - Guardant Health是一家专注于各种实体肿瘤的诊断和分析的精准肿瘤公司，提供精准肿瘤、开发服务和筛查三个领域的服务[2] - GH的Shield产品是一种基于血液的CRC筛查测试，可以检测血液中来自肿瘤释放的DNA，从而发现结直肠癌信号[4] 市场前景 - GH估计美国CRC市场规模约为4500万-5000万，其中80-90%的未筛查人群每年都接受血液检查[5] - GH的Shield产品获得FDA批准后，有望在市场上竞争，吸引更多患者进行筛查[9] - Freenome是一家正在开发竞争性基于血液的CRC筛查测试的私人公司，他们预计将在2026-2027年推出竞争性产品[11] 估值分析 - 我建立了一个完整的三表模型，通过同行多重比较和DCF分析来驱动我的估值[13] - 根据财务模型，公司在精准肿瘤治疗方面的毛利率保持在60%的企业平均水平，但难以找到提升毛利率的真正杠杆[15] - 在运营费用方面，公司的Shield项目每年负担约2亿美元的费用，而悲观情况下则预计会有大幅削减支出的可能[16] 风险与机会 - 公司被归类为更广泛的诊断公司，与Exact Sciences (EXAS)和Natera (NTRA)作为两个最直接的竞争对手，目前的交易倍数低于竞争对手[17] - 历史上，公司一直是诊断领域中较强的公司之一，但目前的估值已经偏离了与竞争对手的典型折扣水平[18] - 重新评估公司的估值水平可能是获利的最直接途径，可能会受到FDA批准或Freenome数据不佳的影响[19] - 公司面临的下行风险可能导致估值进一步下滑，尽管市场中存在一个潜在的即将到来的增长机会[20] - 任何有关利率下调的迹象可能有助于公司和整个行业的估值回升[21] 未来展望 - 尽管DCF分析不是公司的主要估值工具，但在现有假设下进行DCF分析显示公司的现值可能为每股14美元[23] - 如果公司决定终止Shield项目，实际上会对现金流产生积极影响，并可能使股价上涨30%[28] - 公司具有竞争力的产品，有望在2024年获得FDA批准并上市，DCF分析显示公司可能被合理估值，但最直接的盈利途径是通过公司交易倍数的重新评估[29]